Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells

Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC). Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To assess the potential synergistic antitumor effects of picropodophyllin (PPP), an IGF-1R inhibitor, HLF and PLC/PRL...

Descripción completa

Detalles Bibliográficos
Autores principales: TOMIZAWA, MINORU, SHINOZAKI, FUMINOBU, MOTOYOSHI, YASUFUMI, SUGIYAMA, TAKAO, YAMAMOTO, SHIGENORI, SUEISHI, MAKOTO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186500/
https://www.ncbi.nlm.nih.gov/pubmed/25289088
http://dx.doi.org/10.3892/ol.2014.2484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186500/
https://www.ncbi.nlm.nih.gov/pubmed/25289088
http://dx.doi.org/10.3892/ol.2014.2484

Ejemplares similares